- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04023929
Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays (COMPAre)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Newborn infants, particularly those who are born preterm, are vulnerable to infection because of their immature immune systems. Invasive meningococcal disease (IMD) and pertussis both represent significant risks to the newborn infant.
Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, is a devastating illness with a case fatality rate of 10-20% even with intensive treatment. Even infants who survive IMD experience significant disability in 10-20% of cases. Serogroups A, B, C, Y, W and X cause almost all cases of IMD, and in Europe, North America and parts of Latin America serogroup B is responsible for the majority of cases. In the UK there were 747 cases of IMD in 2016/17 and Men B was responsible for 396 (53%) of these. The major burden of disease is in infants under the age of 1 year. Pertussis is a highly infectious respiratory illness caused by Bordetella pertussis which can cause significant morbidity and mortality in young infants. There has been an increase in the incidence of pertussis in the UK, along with other high income countries in recent years which has disproportionately affected young infants.
Infants in the UK are vaccinated against meningococcal group B disease at 2, 4 and 12 months with Bexsero® and against pertussis at 2,3 and 4 months as part of the 6-in-1 vaccine Infanrix hexa®. Additionally, since 2012 pregnant women in the UK have been routinely offered pertussis vaccination during pregnancy to protect the infant in the first few months of life prior to them receiving their own vaccinations.
Serum bactericidal antibody (SBA) assays are important in the assessment of immunity following vaccination and are used in the production, release and licensure of some vaccines and the evaluation of the function of others. SBA assays for pertussis and meningococcal B typically use adult complement from a healthy adult donor pool. There is some concern that using adult complement may not allow an adequate assessment of neonatal immunity. The concentration of most complement components in the neonate is around 10-80% of that in the adult and circulating regulator levels are also reduced. Differences in complement function are more pronounced in preterm infants and the differences in the quality and activation of complement in neonates raises questions about whether an SBA assay using adult complement sources allows an accurate assessment of neonatal immunity.
In this study the investigators will create a pooled complement source for three different gestational ages, ≥37 gestational weeks, 32-36+6 gestational weeks and less than 32 gestational weeks, which will allow the investigators to compare the results of the pertussis and meningococcal SBA assays when using both standard adult complement and a gestational age appropriate complement source. To do this the investigators will collect cord blood samples from deliveries within the three gestational age groups.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Kirsty Le Doare, PhD
- Phone Number: 02087253887
- Email: kiledoar@sgul.ac.uk
Study Locations
-
-
-
London, United Kingdom, SW17 0RE
- Recruiting
- St George's, University of London
-
Contact:
- Vanessa Greening
- Phone Number: 02087253887
- Email: vgreenin@sgul.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pregnant and planning to deliver at St George's University Hospitals NHS Foundation Trust
Exclusion Criteria:
- Aged less than 16 years
- Known complement deficiency
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Term babies
Babies who are born at or after 37 gestational weeks.
|
A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
|
Preterm babies
Babies who are born between 32 and 36+6 gestational weeks.
|
A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
|
Very preterm babies
Babies who are born before 32 gestational weeks.
|
A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SBA assay results
Time Frame: Cord blood sampling will be performed at the time of delivery
|
Comparison of the SBA assay results obtained when using adult human complement compared with a gestationally matched complement source
|
Cord blood sampling will be performed at the time of delivery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Anna Calvert, MBChB, St George's, Univeristy of London
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019.0116
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pertussis
-
National Institute of Allergy and Infectious Diseases...CompletedPertussis | Pertussis ImmunisationUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis (Whooping Cough)France
-
Institut PasteurHopital Universitaire Robert-Debre; Hospices Civils de Lyon; Centre Hospitalier... and other collaboratorsNot yet recruitingBordetella Pertussis, Whooping CoughFrance
-
ILiAD BiotechnologiesActive, not recruitingBordetella Pertussis, Whooping CoughUnited Kingdom, Australia, Costa Rica
-
University of TurkuGlaxoSmithKline; Sanofi Pasteur, a Sanofi CompanyCompleted
-
Institut PasteurAgence de Médecine Préventive, France; Institut Pasteur de Madagascar; Institut...CompletedBordetella Pertussis, Whooping CoughCambodia, Madagascar, Togo
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire
-
GlaxoSmithKlineCompletedPertussis | Pertussis VaccinesHungary
-
University of SouthamptonRecruitingPertussis/Whooping CoughUnited Kingdom
-
Association Clinique Thérapeutique Infantile du...Sanofi; GlaxoSmithKline; Merck Sharp & Dohme LLCRecruitingChildren, Only | Ambulatory | Pertussis/Whooping CoughFrance
Clinical Trials on Cord blood sampling
-
Hospices Civils de LyonCompleted
-
Centre Hospitalier Universitaire DijonRecruiting
-
GlaxoSmithKlineCompletedCytomegalovirus Infections | Infections, CytomegalovirusBelgium
-
Uppsala University HospitalUppsala County Council, SwedenUnknown
-
UCB BIOSCIENCES, Inc.PPD; ParexelCompletedRheumatoid Arthritis | Crohn's Disease | Psoriatic Arthritis | Ankylosing Spondylitis | Axial Spondyloarthritis (AxSpA) | Non-radiographic Evidence-AxSpANetherlands, Switzerland, United States, France
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
CardioRenalCompletedPotassium MeasurementBelgium
-
Bundang CHA HospitalWithdrawnCerebral PalsyKorea, Republic of
-
MinYoung Kim, M.D.Completed